We would love to hear your thoughts about our site and services, please take our survey here.
London South East prides itself on its community spirit, and in order to keep the chat section problem free, we ask all members to follow these simple rules. In these rules, we refer to ourselves as "we", "us", "our". The user of the website is referred to as "you" and "your".
By posting on our share chat boards you are agreeing to the following:
The IP address of all posts is recorded to aid in enforcing these conditions. As a user you agree to any information you have entered being stored in a database. You agree that we have the right to remove, edit, move or close any topic or board at any time should we see fit. You agree that we have the right to remove any post without notice. You agree that we have the right to suspend your account without notice.
Please note some users may not behave properly and may post content that is misleading, untrue or offensive.
It is not possible for us to fully monitor all content all of the time but where we have actually received notice of any content that is potentially misleading, untrue, offensive, unlawful, infringes third party rights or is potentially in breach of these terms and conditions, then we will review such content, decide whether to remove it from this website and act accordingly.
Premium Members are members that have a premium subscription with London South East. You can subscribe here.
London South East does not endorse such members, and posts should not be construed as advice and represent the opinions of the authors, not those of London South East Ltd, or its affiliates.
The consultation process ends on Friday. We'll get their recommendations after that. That's why all these iis have bought in substantially. We might get a bit of a bidding scrum from big pharma. The main suppliers for chronic kidney disease drugs at the moment are AstraZeneca and Thermo Fischer. Not to say that others might not want to take this test. It's worth billions potentially in it's own right. 10 million Americans have diabetes 2. Around 89 million people worldwide also have it. At $950.00 a test it's a valuable product. I think it will go for £2.00.
The talk of suspension is related to a takeover offer, not the company going pop. RENX has staved off pop by the recent issue. The company needs to now emphasise its attractiveness and we could see some nice meaty offers come in over the next few months. GLA
Why the company will be suspended if they done successfully placing for 10 millions?
Subtle. 🙄
Does anybody know what will happen to the shares once the company is is suspended? Will all the shareholders still holding RENX shares lose them? Thank you
No holdings rns today as we have had many over the last couple of weeks.
Unless they are happy with what they have of course?
It was opened at the wrong price. I was going to buy at 32.5p but from the bell it was 36.4p to buy so I didn't bother. It looks like no one else bothered either - or just a few took small punts. If it had opened at 32.5p there would have been a flurry of buying and it would probably be up around the 40p mark by now.
Let's see if we can match the U.S today and see what they do thos afternoon.
Institutions are certainly loading up here so follow the money as can't be long before we are suspended and a buy out offer comes in.
Surprised by the lack of movement here
Recent Pharma/PE deals have included a deferred element….I would not be surprised to see much of the value over the current company value offered as a 2 year warrant payable on certain performance metrics.
Differences in the timing of any takeover payments may be significant as may be the value….
The current mcap is around £40m
What would you take of these options:
£80m upfront?
£60m upfront and 60m deferred?
£40m upfront and 200m deferred?
When they suspend it here, people won't be able to buy again. Shareholders will simply vote on sale price and going by the information available its in excess of £1.40.
Corporations know this hence buying all they can. Simply transferring the stock from the weak holders to the companies.
A great watch.
32.5% up at $1.15 - that's 45p equivalent - with 30 minutes to go to close.
I am getting the price from my IG account which includes US stocks. Ii is also available on Yahoo Finance under the ticker RNLX - link below.
https://uk.finance.yahoo.com/quote/RNLX?.tsrc=fin-srch
25% up currently
Have you a link please?
Thankyou in advance.
US up over 20% now at 7pm GMT. Over 40p equivalent if it continues to closing.
Not suspended. It will be when they consider the offers.
Suspended why?
Dont forget -
RNS Number : 4140F
Renalytix PLC
04 March 2024
Renalytix plc (NASDAQ: RNLX) (LSE: RENX), an artificial intelligence-enabled in vitro diagnostics company, focused on optimizing clinical management of kidney disease to drive improved patient outcomes and advance value-based care provides the following update in regard to an unsolicited approach from a possible strategic acquiror, launch of a Formal Sale Process, and its advanced financing activities.
Formal Sale Process
Renalytix has received an unsolicited approach from a large and well-capitalised publicly listed strategic diagnostics company, which is in the process of evaluating an acquisition of the entire issued, and to be issued, share capital of the Company.
Therefore, the Company has commenced a review of all available options, including a possible sale of the Company and/or its assets, and has commenced a formal sale process (as referred to in Note 2 on Rule 2.6 of the City Code on Takeovers and Mergers) (the "Formal Sale Process"). The Formal Sale Process will enable the Board and its advisers to conduct an orderly process and engage more widely with all potentially interested parties, with a view to optimising the outcome for Renalytix's shareholders. It remains possible that, following completion of the Formal Sale Process, the Board will consider that Renalytix and its shareholders would be best served by alternative strategic options available to the Company, including by Renalytix continuing to trade on AIM and Nasdaq as an independent entity.
More and more interesting as we get to further clarity on investors in the placing. In addition to Harwood, Sinai, Penwater and Polar - Lombard Odier took 1.7m shares and billionaire financier Nathanial Rothschilds investments holdings business picking up a similar amount - taking his total holding to 4.7%. Updated list of significant shareholders holding 3%+ is going to be very interesting. SB
Not seen this many RNS on a share for ages. Corporations taking position before its suspended likely.
The future prospects for *Renalytix plc* appear promising based on several key developments and catalysts:
1. *Potential Acquisition*: Renalytix AI is currently engaged in a formal sale process and has garnered interest from a well-capitalized strategic diagnostics company. Such potential acquisition scenarios often act as positive catalysts for a stock¹.
2. *Financial Strengthening Efforts*: Despite relatively low cash reserves, Renalytix AI has executed critical milestones in the past year. The company's ongoing discussions to raise either equity or debt from new and existing investors demonstrate efforts to strengthen its balance sheet¹.
3. *Total Addressable Market: Renalytix AI operates in a sizable total addressable market, estimated to be over *$13 billion**. This suggests significant growth potential¹.
4. *Upcoming Catalysts*: The company has several upcoming catalysts that could drive its value:
- *Potential Acquisition*: If the acquisition proceeds, it could positively impact the stock.
- *Financial Improvements*: Efforts to enhance the financial position.
- *Advancements in KidneyIntelX*: Renalytix AI's flagship product, KidneyIntelX, has the potential to contribute to its growth¹.
5. *Analyst Ratings: BTIG analyst Mark Massaro has reiterated a **Buy rating* on RNLX stock, emphasizing the positive factors mentioned above. Stifel Nicolaus also maintained a Buy rating with a $5.00 price target¹².
In summary, Renalytix AI's focus on kidney disease risk assessment, clinical care, patient stratification, and drug target discovery positions it well for future growth opportunities¹. 🚀📈
Source: Conversation with Bing, 15/03/2024
(1) Buy Rating Affirmed for Renalytix AI Amidst Potential Acquisition and .... https://markets.businessinsider.com/news/stocks/buy-rating-affirmed-for-renalytix-ai-amidst-potential-acquisition-and-strong-market-prospects-1033130607.
(2) Strong Buy for Renalytix AI: Undervalued Stock with Promising Market .... https://markets.businessinsider.com/news/stocks/strong-buy-for-renalytix-ai-undervalued-stock-with-promising-market-prospects-and-strategic-growth-catalysts-1033048517.
(3) Mount Sinai Initiates System-wide Scale-Up of Renalytix KidneyIntelX .... https://renalytix.com/mount-sinai-initiates-system-wide-scale-up-of-renalytix-kidneyintelx-enabled-health-care-model/.
Now that the Placing is out of the way and we're 12M richer, hopefully we'll climb back up into the 40s which was where we were settling before the Placing came along. According to Simply Wall St. revenue is forecast to grow 108.13% per year. This Share has been very volatile lately. Sentiment is high with a bid pending, another day of high volumes could see this climb rapidly again.
It's an impressive list. I wonder what price they hoping to get for the business?
In addition to Harwood picking up 4m shares in the placing and Sinai 9.3m; Polar picked up 9.7m and Penwater 4.7m (although they did initially note they had taken 2.6m). Not 100% sure how these shares are split over the 'first close' issue (19m shares) and the total placing of 46.8m shares (which might might explain Penwater's updates). Positive imo - can't imagine Polar and Penwater throwing in further cash without a strong internal case on likely return and challenging Renx on progress. Wonder if Jefferson picked up a slice. SB
*agree to disagree. Damn spellchecker!